<DOC>
	<DOCNO>NCT01042392</DOCNO>
	<brief_summary>This prospective multicenter , double blind study evaluate efficacy safety aliskiren versus ramipril patient moderate systolic essential hypertension .</brief_summary>
	<brief_title>Efficacy Aliskiren Compared Ramipril Treatment Moderate Systolic Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Outpatients &gt; 18 year Male female patient . Female patient must either postmenopausal one year , surgically sterile , use effective contraceptive method Patients essential hypertension , previously treat antihypertensive singledrug therapy , either uncontrolled intolerant . BP thresholds visit 1 : For patient previously treat uncontrolled : 140≤ office SBP &lt; 180 mmHg For patient previously treat , control intolerant : office SBP≥130 mmHg BP thresholds visit 2 ( patient ) : 160≤office SBP &lt; 180 mmHg AND 155≤home SBP &lt; 175 mmHg ( 3day period home blood pressure monitor randomization ) Women childbearing potential use effective method contraception Severe hypertension ( office BP ≥ 180/110 mmHg ) Impossibility stop abruptly previous antihypertensive treatment visit 1 Patients previously untreated patient treat two three antihypertensive medication History evidence secondary form hypertension History hypersensitivity ACEi renin inhibitor History heart failure , stroke coronary heart disease Serum potassium ≥ 5.2 mmol/l Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Moderate systolic hypertension - adult - aliskiren -ramipril</keyword>
</DOC>